Drug Profile
Research programme: infectious disease vaccines - iBio
Alternative Names: Anthrax vaccine - iBio; Anthrax-plague combination vaccine - iBio; Cancer vaccine - iBio; HPV vaccine - iBio; Influenza A virus H7N9 vaccine - iBio; Malaria vaccine - iBio; Plague vaccine - iBioLatest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator INB:Biotechnologies
- Developer iBio Inc
- Class Anthrax vaccines; Cancer vaccines; Influenza A virus H7N9 vaccines; Papillomavirus vaccines; Parasitic vaccines; Plague vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Bacterial infections; Parasitic infections; Viral infections
Highest Development Phases
- No development reported Anthrax; Cancer; Human papillomavirus infections; Influenza A virus H7N9 subtype; Plague
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Cancer in USA
- 18 Oct 2016 iBio has patent protection for iBioModulator™ thermostable immunomodulator protein technology in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anthrax in USA (PO)